Induction Erlotinib Therapy in Stage III A (N2) Non-Small Cell Lung Cancer (NSCLC)

NCT00600587 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

24

Enrollment

OTHER

Sponsor class

Conditions

Carcinoma, Non-Small-Cell Lung

Interventions

DRUG: neoadjuvant erlotinib therapy
DRUG: neoadjuvant gemcitabine/carboplatin therapy

Sponsor

Guangdong Provincial People's Hospital